Payment overview · 2025
General Payments
$203.55
11 reported records · 7 companies
Healthcare provider profile · identity verified
Brice Tompkins, MD
Allopathic & Osteopathic Physicians|Family Medicine · BONITA SPRINGS, FL · NPI 1114904299
Verified facts
What the public records show
CMS Open Payments records show Brice Tompkins, MD received $203.55 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.23 | 26.1% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $32.15 | 15.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.96 | 15.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.21 | 14.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.57 | 11.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.05 | 9.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.38 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.55 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.60 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1589 | 458 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1584 | 482 |
| Amlodipine Besylate | Amlodipine Besylate | 875 | 260 |
| Losartan Potassium | Losartan Potassium | 550 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 147 |
| Lisinopril | Lisinopril | 493 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 431 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 406 | 147 |
| Metformin Hcl | Metformin Hcl | 302 | 87 |
| Omeprazole | Omeprazole | 266 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 259 | 75 |
| Ezetimibe | Ezetimibe | 253 | 87 |
| Simvastatin | Simvastatin | 237 | 72 |
| Allopurinol | Allopurinol | 228 | 64 |
| Montelukast Sodium | Montelukast Sodium | 224 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 194 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 55 |
| Alprazolam | Alprazolam | 159 | 67 |
| Trazodone Hcl | Trazodone Hcl | 157 | 64 |
| Methylprednisolone | Methylprednisolone | 155 | 134 |
| Gabapentin | Gabapentin | 153 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 64 |
| Atenolol | Atenolol | 148 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 147 | 45 |
| Prednisone | Prednisone | 147 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 40 |
| Sertraline Hcl | Sertraline Hcl | 112 | 37 |
| Potassium Chloride | Potassium Chloride | 104 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 29 |
| Synthroid | Levothyroxine Sodium | 98 | 27 |
| Azithromycin | Azithromycin | 95 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 36 |
| Ozempic | Semaglutide | 87 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 32 |
| Valsartan | Valsartan | 83 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 22 |
| Buspirone Hcl | Buspirone Hcl | 73 | 25 |
| Carvedilol | Carvedilol | 73 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 19 |
| Irbesartan | Irbesartan | 71 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 64 | 17 |
| Lorazepam | Lorazepam | 64 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 17 |
| Azelastine Hcl | Azelastine Hcl | 57 | 29 |
| Paxlovid | Nirmatrelvir/Ritonavir | 55 | 52 |
| Bupropion Xl | Bupropion Hcl | 54 | 18 |
| Furosemide | Furosemide | 53 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 22 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Benazepril Hcl | Benazepril Hcl | 48 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 14 |
| Eliquis | Apixaban | 44 | 18 |
| Meloxicam | Meloxicam | 44 | 18 |
| Valacyclovir | Valacyclovir Hcl | 42 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | 11 |
| Famotidine | Famotidine | 33 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 31 |
| Mupirocin | Mupirocin | 31 | 29 |
| Meclizine Hcl | Meclizine Hcl | 30 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 11 |
| Glimepiride | Glimepiride | 29 | 12 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 13 |
| Finasteride | Finasteride | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 23 |
| Diazepam | Diazepam | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 22 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 21 |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Glipizide | Glipizide | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.55 · 11 records | Lilly USA, LLC | AREXVY, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, LOREEV XR, MOUNJARO, SHINGRIX, TERIPARATIDE, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error